National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Romiplostim (Nplate®) is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.

Commenced Completed Outcome
02/04/2015 27/05/2015 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.